

Yaacov Ben-David

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712027/publications.pdf>

Version: 2024-02-01

56
papers

1,753
citations

331670

21
h-index

289244

40
g-index

58
all docs

58
docs citations

58
times ranked

2026
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. <i>Nature Genetics</i> , 1998, 19, 199-202.	21.4	267
2	Friend virus-induced erythroleukemia and the multistage nature of cancer. <i>Cell</i> , 1991, 66, 831-834.	28.9	256
3	The role of Fli-1 in normal cell function and malignant transformation. <i>Oncogene</i> , 2000, 19, 6482-6489.	5.9	112
4	Fli-1, an Ets-Related Transcription Factor, Regulates Erythropoietin-Induced Erythroid Proliferation and Differentiation: Evidence for Direct Transcriptional Repression of the <i>Rb</i> Gene during Differentiation. <i>Molecular and Cellular Biology</i> , 1999, 19, 4452-4464.	2.3	97
5	The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. <i>Blood</i> , 2012, 119, 4486-4498.	1.4	93
6	Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2018, 23, 112-126.	6.4	58
7	Retroviral insertional activation of the Fli-3 locus in erythroleukemias encoding a cluster of microRNAs that convert Epo-induced differentiation to proliferation. <i>Blood</i> , 2007, 110, 2631-2640.	1.4	52
8	The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. <i>Blood</i> , 2010, 116, 428-436.	1.4	51
9	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. <i>Oncogene</i> , 2000, 19, 395-402.	5.9	50
10	Design and synthesis of novel C14-urea-tetrandrine derivatives with potent anti-cancer activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1968-1980.	5.5	40
11	The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. <i>Blood</i> , 2005, 105, 4500-4507.	1.4	34
12	MDA-7/IL-24 functions as a tumor suppressor gene <i>in vivo</i> in transgenic mouse models of breast cancer. <i>Oncotarget</i> , 2015, 6, 36928-36942.	1.8	34
13	Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia. <i>Oncogene</i> , 2000, 19, 2296-2304.	5.9	33
14	Vascular Endothelial Growth Factor is a Positive and Negative Regulator of Tumor Growth. <i>Cancer Research</i> , 2010, 70, 863-867.	0.9	29
15	Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis. <i>Cell Death and Disease</i> , 2019, 10, 117.	6.3	29
16	Fangchinoline derivatives induce cell cycle arrest and apoptosis in human leukemia cell lines via suppression of the PI3K/AKT and MAPK signaling pathway. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111898.	5.5	27
17	The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. <i>Oncogene</i> , 2000, 19, 1419-1427.	5.9	26
18	Enhanced natural-killer cell and erythropoietic activities in VEGF-overexpressing mice delay F-MuLV-induced erythroleukemia. <i>Blood</i> , 2007, 109, 2139-2146.	1.4	24

#	ARTICLE	IF	CITATIONS
19	Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes. <i>International Journal of Oncology</i> , 2018, 53, 2705-2714.	3.3	24
20	Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence. <i>Oncogene</i> , 1999, 18, 5525-5534.	5.9	23
21	Synthesis of novel guttiferone E and xanthochymol derivatives with cytotoxicities by inducing cell apoptosis and arresting the cell cycle phase. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 765-780.	5.5	23
22	Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. <i>FEBS Journal</i> , 2018, 285, 4631-4645.	4.7	22
23	microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. <i>JCI Insight</i> , 2017, 2, .	5.0	22
24	A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to megakaryocytic differentiation and suppress leukemogenesis. <i>Oncotarget</i> , 2017, 8, 16728-16743.	1.8	22
25	Friend virus-induced erythroleukemias: a unique and well-defined mouse model for the development of leukemia. <i>Anticancer Research</i> , 2003, 23, 2159-66.	1.1	22
26	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. <i>Nature Communications</i> , 2020, 11, 1825.	12.8	21
27	Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents. <i>MedChemComm</i> , 2018, 9, 1131-1141.	3.4	19
28	BW18, a C-21 steroidal glycoside, exerts an excellent anti-leukemia activity through inducing S phase cell cycle arrest and apoptosis via MAPK pathway in K562 cells. <i>Biomedicine and Pharmacotherapy</i> , 2019, 112, 108603.	5.6	18
29	Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3 TM , 5 TM -diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2216.	4.1	16
30	Syntheses and anti-cancer activities of glycosylated derivatives of diosgenin. <i>Chemical Research in Chinese Universities</i> , 2017, 33, 80-86.	2.6	15
31	Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis. <i>Oncogene</i> , 2003, 22, 3452-3462.	5.9	14
32	Novel racemosin B derivatives as new therapeutic agents for aggressive breast cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 6096-6104.	3.0	14
33	FLI1 Induces Megakaryopoiesis Gene Expression Through WAS/WIP-Dependent and Independent Mechanisms; Implications for Wiskott-Aldrich Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 607836.	4.8	14
34	Suppression of Her2/Neu mammary tumor development in <i>mda-7/IL-24</i> transgenic mice. <i>Oncotarget</i> , 2015, 6, 36943-36954.	1.8	14
35	Selective ERK1/2 agonists isolated from <i>Melia azedarach</i> with potent anti-leukemic activity. <i>BMC Cancer</i> , 2019, 19, 764.	2.6	12
36	Erythropoietin Signaling in the Microenvironment of Tumors and Healthy Tissues. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1223, 17-30.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression. <i>Oncogene</i> , 2001, 20, 2291-2300.	5.9	11
38	Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. <i>Blood</i> , 2009, 114, 1831-1841.	1.4	10
39	Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect. <i>International Journal of Oncology</i> , 2017, 51, 456-466.	3.3	9
40	Current insights into the role of Fli-1 in hematopoiesis and malignant transformation. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 163.	5.4	9
41	A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3. <i>Communications Biology</i> , 2020, 3, 732.	4.4	8
42	ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes. <i>BMC Cancer</i> , 2021, 21, 680.	2.6	8
43	An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 242.	8.6	8
44	Transcription factor Fli-1 as a new target for antitumor drug development. <i>International Journal of Biological Macromolecules</i> , 2022, 209, 1155-1168.	7.5	8
45	Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. <i>Oncogene</i> , 2004, 23, 2305-2314.	5.9	7
46	Associations Between XPD Lys751Gln Polymorphism and Leukemia: A Meta-Analysis. <i>Frontiers in Genetics</i> , 2018, 9, 218.	2.3	6
47	FLI1 regulates inflammation-associated genes to accelerate leukemogenesis. <i>Cellular Signalling</i> , 2022, 92, 110269.	3.6	5
48	Contiguous arrangement of p45 NFE2, HnRNP A1, and HP1? on mouse chromosome 15 and human chromosome 12: Evidence for suppression of these genes due to retroviral integration within the Fli-2 locus. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 91-95.	2.8	4
49	Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia. <i>International Journal of Oncology</i> , 2013, 43, 169-176.	3.3	4
50	Enhancement of SCA1 Positive Hematopoietic Progenitors in Polycythemic Mice Inhibits Leukemogenesis. <i>Blood</i> , 2008, 112, 5245-5245.	1.4	4
51	Ubash3b promotes TPA-mediated suppression of leukemogenesis through accelerated downregulation of PKC ζ protein. <i>Biochimie</i> , 2021, 184, 8-17.	2.6	3
52	Propofol mediates pancreatic cancer cell activity through the repression of ADAM8 via SP1. <i>Oncology Reports</i> , 2021, 46, .	2.6	3
53	Pro-inflammatory effect of a traditional Chinese medicine formula with potent anti-cancer activity in vitro impedes tumor inhibitory potential in vivo. <i>Molecular and Clinical Oncology</i> , 2016, 5, 717-723.	1.0	2
54	FLI1 promotes protein translation via the transcriptional regulation of MKNK1 expression. <i>International Journal of Oncology</i> , 2020, 56, 430-438.	3.3	2

#	ARTICLE	IF	CITATIONS
55	A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer. <i>Cancer Gene Therapy</i> , 2022, 29, 1590-1599.	4.6	2
56	A racemosin B derivative, C25, suppresses breast cancer growth via lysosomal membrane permeabilization and inhibition of autophagic flux. <i>Biochemical Pharmacology</i> , 2022, 201, 115060.	4.4	1